1. Home
  2. WVE vs BOW Comparison

WVE vs BOW Comparison

Compare WVE & BOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • BOW
  • Stock Information
  • Founded
  • WVE 2012
  • BOW 2020
  • Country
  • WVE Singapore
  • BOW United States
  • Employees
  • WVE N/A
  • BOW N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • BOW Property-Casualty Insurers
  • Sector
  • WVE Health Care
  • BOW Finance
  • Exchange
  • WVE Nasdaq
  • BOW Nasdaq
  • Market Cap
  • WVE 915.6M
  • BOW 1.1B
  • IPO Year
  • WVE 2015
  • BOW 2024
  • Fundamental
  • Price
  • WVE $7.79
  • BOW $26.54
  • Analyst Decision
  • WVE Strong Buy
  • BOW Buy
  • Analyst Count
  • WVE 16
  • BOW 6
  • Target Price
  • WVE $20.19
  • BOW $35.67
  • AVG Volume (30 Days)
  • WVE 2.1M
  • BOW 371.4K
  • Earning Date
  • WVE 11-11-2025
  • BOW 11-04-2025
  • Dividend Yield
  • WVE N/A
  • BOW N/A
  • EPS Growth
  • WVE N/A
  • BOW 41.97
  • EPS
  • WVE N/A
  • BOW 1.47
  • Revenue
  • WVE $93,946,000.00
  • BOW $492,071,000.00
  • Revenue This Year
  • WVE N/A
  • BOW $19.49
  • Revenue Next Year
  • WVE $6.85
  • BOW $21.79
  • P/E Ratio
  • WVE N/A
  • BOW $18.05
  • Revenue Growth
  • WVE N/A
  • BOW 41.21
  • 52 Week Low
  • WVE $5.28
  • BOW $23.70
  • 52 Week High
  • WVE $16.74
  • BOW $42.29
  • Technical
  • Relative Strength Index (RSI)
  • WVE 52.90
  • BOW 43.93
  • Support Level
  • WVE $6.91
  • BOW $25.53
  • Resistance Level
  • WVE $8.31
  • BOW $27.14
  • Average True Range (ATR)
  • WVE 0.42
  • BOW 1.07
  • MACD
  • WVE 0.15
  • BOW 0.18
  • Stochastic Oscillator
  • WVE 69.65
  • BOW 64.69

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About BOW Bowhead Specialty Holdings Inc. Common Stock

Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.

Share on Social Networks: